KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data

Simple item page
dc.contributor.authorZhu, Songling
dc.contributor.authorBao, Hongxia
dc.contributor.authorZhang, Meng-Chun
dc.contributor.authorLiu, Huidi
dc.contributor.authorWang, Yao
dc.contributor.authorLin, Caiji
dc.contributor.authorZhao, Xingjuan
dc.contributor.authorLiu, Shu-Lin
dc.date.accessioned2022-06-19T00:03:28Z
dc.date.available2022-06-19T00:03:28Z
dc.date.issued2022-06-16
dc.date.updated2022-06-19T00:03:27Z
dc.description.abstractAbstract Background Ovarian cancer (OC) is among the deadliest malignancies in women and the lack of appropriate markers for early diagnosis leads to poor prognosis in most cases. Previous studies have shown that KAZN is involved in multiple biological processes during development, such as cell proliferation, differentiation, and apoptosis, so defects or aberrant expression of KAZN might cause queer cell behaviors such as malignancy. Here we evaluated the KAZN expression and methylation levels for possible use as an early diagnosis marker for OC. Methods We used data from Gene Expression Omnibus (GEO) microarrays, The Cancer Genome Atlas (TCGA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) to investigate the correlations between KAZN expression and clinical characteristics of OC by comparing methylation levels of normal and OC samples. The relationships among differentially methylated sites in the KAZN gene, corresponding KAZN mRNA expression levels and prognosis were analyzed. Results KAZN was up-regulated in ovarian epithelial tumors and the expression of KAZN was correlated with the patients’ survival time. KAZN CpG site cg17657618 was positively correlated with the expression of mRNA and the methylation levels were significantly differential between the group of stage “I and II” and the group of stage “III and IV”. This study also presents a new method to classify tumor and normal tissue in OC using DNA methylation pattern in the KAZN gene body region. Conclusions KAZN was involved in ovarian cancer pathogenesis. Our results demonstrate a new direction for ovarian cancer research and provide a potential diagnostic biomarker as well as a novel therapeutic target for clinical application.
dc.identifier.citationBMC Cancer. 2022 Jun 16;22(1):662
dc.identifier.doihttps://doi.org/10.1186/s12885-022-09747-2
dc.identifier.urihttp://hdl.handle.net/1880/114755
dc.identifier.urihttps://doi.org/10.11575/PRISM/44333
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleKAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12885_2022_Article_9747.pdf
Size:
3.51 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications